Skip to content
Serna Bio logo

Serna Bio

Serna Bio is a YC Winter 2021 (W21) company. Based in Ontario, CA, USA; Remote. Team of 5.

  • Biotech
  • Drug discovery

About Serna Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Serna Bio develops small molecules that regulate protein expression by targeting RNA directly, rather than proteins themselves. Its AI-native discovery platform maps druggable RNA structures and screens RNA-small molecule interactions to identify and optimize drug candidates. The platform opens therapeutic targets that conventional protein-focused drug discovery cannot reach, covering protein downregulation, upregulation, and splicing correction.

Go-to-market

Serna Bio advances its own internal pipeline built on the platform, positioning the technology toward pharmaceutical partnerships targeting RNA-driven diseases.

From the Y Combinator listing

How Serna Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Genetic Medicine with Small Molecules

Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Ontario, CA, USA; Remote
Team size
5
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works